IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Merck & Co., Inc.

Q2 2025 Holdings

Filed 2025-08-13 | 13 holdings | $215.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Personalis Inc(PSNL)COM71535D106$92.1M14,044,94342.7%
Moderna Inc(MRNA)COM60770K107$63.7M2,308,19029.5%
Kymera Therapeutics Inc(KYMR)COM501575104$33.7M772,16515.6%
Entrada Therapeutics IncCOM29384C908$11.7M1,739,7685.4%
Alector Inc(ALEC)COM014442107$5.0M3,545,7192.3%
Evaxion Biotech A/SSPONSORED ADS29970R204$3.0M1,214,1261.4%
Sutro Biopharma IncCOM869367102$1.9M2,723,5090.9%
Lava Therapeutics NVSHSN51517105$1.5M1,149,3450.7%
Viridian Therapeutics Inc(VRDN)COM92790C104$1.3M93,4140.6%
Xilio Therapeutics Inc(XLO)COM98422T100$1.0M1,483,7580.5%
Carisma Therapeutics Inc(CARM)COM14216R101$576.9K1,473,2400.3%
Neuphoria Therapeutics Inc(NEUP)COM64136E102$71.2K10,0270.0%
Tuhura Biosciences(HURA)COM898920103$31.1K13,9500.0%